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Abstract
Introduction There is no unanimous consensus on the
clinical features to define breakthrough cancer pain
(BTcP). The current project aimed to investigate the
opinion of a panel of experts on cancer pain on how to
define, diagnose, assess, treat and monitor BTcP.
Materials and methods A two-round Spanish multi-cen-
tre exploratory Delphi study was conducted with medical
experts (n = 90) previously selected from Medical
Oncology Services, Radiation Oncology, Palliative Care/
Home Care Teams, and Pain Units. The study intended to
seek experts’ consensus and to define a set of recommen-
dations for the management of BTcP.
Results It was generally agreed that, definition of BTcP
implies that baseline pain should be controlled (84 %),
although not necessarily with opioids (only 30 %); there
must be exacerbations (98.9 %); the duration of each epi-
sode should last\1 h (70 %); the intensity of pain C7 out
of 10 (67.8 %); and the number of flares per day should not
be less than four. All participants supported the use of the
Davies algorithm for the diagnosis. The use of a ‘Patient
Diary’ was highly recommended. The optimal treatment
should have a rapid onset, a short-acting analgesic effect
(1–2 h) and transmucosal nasal or oral administration. It
was considered very important to develop protocols for the
management of cancer pain.
Conclusions The present Delphi study identified a set of
recommendations to define, assess and monitor BTcP.
Keywords Breakthrough cancer pain  Baseline cancer
pain  Management  Consensus  Cancer  Delphi
Introduction
In 1990, Portenoy and Hagen published an article about a
specific pain syndrome that is known as ‘‘irruptive pain’’,
or by the term ‘‘breakthrough pain’’. Breakthrough pain has
been defined as a ‘transient exacerbation of pain that occurs
either spontaneously, or in addition to a stable and ade-
quately controlled background pain, generally treated with
major opioids’ [1]. Later on, in 2004, same authors
excluded the condition of opioid treatment of background
pain, and defined it as a ‘‘transitory exacerbation of pain
experienced by a patient who has relatively stable and
adequately controlled baseline cancer pain’’ [2].
The requirement of background pain to be controlled
allows us to distinguish BTcP from end-dose pain flares
and those flares that occurred during the drug analgesics
titration of the background pain. To emphasize these
differences, Davies et al. [3] defined BTcP as a ‘‘tran-
sitory exacerbation of pain that occurs, either sponta-
neously or associated with predictable factors or not,
even though the baseline pain is relatively stable and
well controlled.’’
A working group from the European Association of
Palliative Care suggested, for linguistic reasons, to replace
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the term ‘‘breakthrough pain’’ with other terms such as
‘‘episodic pain’’ or ‘‘transitory pain’’ [4]. However, the
term ‘‘breakthrough pain’’ is frequently used in clinical
practice, and will be the one used throughout this paper.
In 2012, several Spanish medical societies––Sociedad
Espan˜ola de Oncologı´a Me´dica (SEOM); Sociedad Espa-
n˜ola de Oncologı´a Radiotera´pica (SEOR), Sociedad
Espan˜ola de Cuidados Paliativos (SECPAL) and Sociedad
Espan˜ola de Dolor (SED)––adopted a consensus document
in which the term ‘‘breakthrough pain’’ refers to a sudden
and transient exacerbation of pain of high intensity and
short duration (typically less than 20–30 min), which
appears over the baseline of a stable persistent pain, when
this has been reduced to a tolerable level by the funda-
mental use of strong opioids [5]. This definition, still in
force for many experts [6], again raises the controversy that
background cancer pain should be controlled with opioids.
To consider that baseline pain is adequately controlled,
some authors assume that the average intensity of pain
must be less than four on a verbal numerical rating scale
(VNRS) or visual analogue scale (VAS) from 0 to 10, and
the maximum number of episodes of BTcP should be three
per day [7]. However, a recent study described BTcP in a
diverse population of cancer patients that included people
who suffered up to 24 episodes a day [8], while still con-
sidering these episodes as BTcP, and thus assuming that
baseline pain is adequately controlled.
Despite all this knowledge, BTcP is currently under-
diagnosed and under-treated. An epidemiological study
developed by the International Association for the Study of
Pain (IASP) about the features of tumour pain, showed
large differences among continental geographical areas in
terms of the frequency of diagnosis of BTcP [9]. Even
today, there is no validated method for assessment,
although a proper evaluation should include a complete
analysis of the pain history, frequency and duration of
episodes, monitoring the intensity of pain using VNRS or
VAS scales, type of pain, triggers, previous medication,
and effectiveness of rescue therapy as well as a physical
examination of the patient [1].
Around 60–90 % of cancer patients die in pain [10].
Regarding therapeutic options, we know that the charac-
teristics that define BTcP––rapid onset, high intensity and
short duration––do not fit the mode of action of traditional
opioids. The ideal opioid for the treatment of BTcP should
have a rapid onset and a short duration of action [11]. At
present, fentanyl, which is available for administration in
different forms, is the drug best suited to this profile [11,
12].
Those facts enclosed in the definition of BTcP as well as
procedures for its diagnosis, assessment and monitoring
may influence the choice of a treatment and consequently
patient outcomes. Hence the importance of obtaining a
consensus on these issues from a broad group of experts in
cancer pain.
The aim of this study was to explore the opinion of an
expert panel in cancer pain, regarding the clinical features
to define BTcP; to understand the procedures and assess-
ment scales and monitoring of BTcP in clinical practice in
Spain; to uncover the discrepancies; and to find areas of
consensus to develop recommendations for the manage-
ment of BTcP.
Materials and methods
The Delphi method is commonly used to obtain the collec-
tive vision of a group of experts on a subject, and is able to
extract and clarify the judgement of the group [13]. Its pre-
dictive capacity is based on the systematic use of intuitive
judgement, pronounced by a group of experts, which iden-
tifies the degree of consensus and points of disagreement
regarding a specific topic. It involves sending a succession of
anonymous questionnaires to a group of previously selected
experts, to try to get consensus, but providing anonymity to
participants. After finishing the first round, each member
receives a summary of responses corresponding to the first
questionnaire. Then, each expert has to revise their previous
answers, compare them with those of the rest of the panel-
lists, and answer the next questionnaire, trying to seek the
widest possible consensus [14, 15].
A total of 90 experienced and trained experts on cancer
pain, homogenously distributed across Spain, were selected
from different units: medical oncology (n = 21), radiation
oncology (n = 19), pain units (n = 26) and palliative care/
home care (n = 24).
The first questionnaire consisted of 44 questions divided
into six blocks, each of them with specific objectives
(Table 1). The first round of questions (44 in total) inves-
tigated the opinion of experts on the criteria for the defi-
nition of BTcP, assessment, screening and diagnostic
methods, and how the treatment and monitoring should
look like. The mean and standard deviation of the
responses were calculated for each question and these data
were showed in the second round of the questionnaire; in
this way each participant knew the averaged values of the
responses to the first round, and they could vary their
responses at this point.
The second round included only those topics that did not
reach consensus (26 questions) and was aimed to clarify
the most controversial issues generated during the first
round, to inquire any additional issue raised by the results
of the first questions, and to agree on some general
recommendations.
An online application was developed to administer the
questionnaires and to share all information related to the
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study. Participants provided their responses of both rounds
of the survey directly in the online application.
Data analysis
A descriptive study of the variables was carried out
according to their type: for numeric variables, measures of
central tendency and dispersion (sample size, mean, median,
minimum, maximum, standard deviation, 95 % CI, Q1 and
Q3) were applied. For the categorical variables, frequency
distribution tables and percentages (n, %) were provided.
For the evaluation of some of the answers, a 7-point
ordinal rating scale of the Likert type (where 1 = strongly
disagree/never/never recommend, and 7 = strongly agree/
always/always recommend) was used.
A pairedwise analysis was carried out by means of a
Student’s t test to analyse the change of the responses
between the two rounds. A two-sided 0.05 significance
level was set.
Results
On the definition, diagnose and management
of BTcP
Half of the panel understood that the patient must be taking
analgesics on regular basis to achieve background pain
relief, and 84 % stated the importance of an adequate
control of cancer pain in the definition of BTcP (Fig. 1a).
Likewise, most panellists (98.9 %) defined BTcP as the
occurrence of spontaneous or incidental exacerbations of
pain. The average duration of each episode must be
B60 min and pain intensity C7 points out of 10. Only 30 %
of respondents agreed on the mandatory nature of taking
opioid analgesics to define background pain (Fig. 1a, b).
Repeated exacerbations of pain before the next dose of
analgesics were not classified as BTcP (Fig. 1b).
In the first survey, 34 % of participants recognized not
to use the Davies algorithm (Fig. 2) mainly because of the
lack of awareness. In the second survey, the question was
reformulated and 100 % admitted to ask their patients, and
also advise to do that, about the parameters of the Davies
algorithm, even if it is not used as an algorithm as such.
Around 68 % of experts confirmed to use a sort of
‘Patient Diary’. Among the parameters to be collected on
the diary, the most voted were date and time of each epi-
sode, its duration and intensity, the administered rescue
dose, time to/degree of pain relief, and side effects,
including the recommendation to contact the doctor if more
than three rescues per day were required (together with a
contact phone number).
To better characterize BTcP, registration of pain anal-
gesics taken by the patient was deemed as the most
important factor to be gathered on the clinical history
(average Likert score of 6.7 out of 7). Indeed, this item was
the most frequently asked to the patient (88.9 %) (Table 2).
Other important factors were: the number of flares per day
or week, the adherence to pain treatment (both with an
average Likert score of 6.6); duration (6.4) and intensity
(6.5) of flares; either spontaneous occurrence of flares or
triggered by some activity (6.5); and the efficacy of anal-
gesics (6.4). Some important factors to characterize BTcP
were hardly taken into account though. Just over 50 % of
the experts always ask about the impact of pain on daily
life, and only 43.3 % try to discover in a systematic way
the strategies that patient uses to relieve pain (Table 2).
Participants responded about several topics to be noted
down on the clinical history of each patient and categorized
their importance (Fig. 3). Most experts agreed on the
importance (Likert score of 6.8 out of 7.0) to record the
medication for baseline and breakthrough pain. It was also
stated the convenience to register the clinical features
(71.3 %) and the diagnostic of BTcP (85 %), and to a
lesser extent (51.7 %) its impact on quality of life.
Table 1 Topics and objectives from the first questionnaire
Subject to evaluate Objective
Definition of breakthrough of cancer pain Investigate the level of agreement for each purposed definition
BTcP patients Estimate the number of patients with breakthrough cancer pain
Importance of BTcP and drawbacks in
managing
Ascertain the importance of managing breakthrough cancer pain within the frame of each
cancer patient
Detection, diagnose and characterization of
breakthrough cancer pain
Get knowledge on the methods to detect, diagnose, and evaluate breakthrough cancer pain in
routine clinical praxis
Treatment of breakthrough cancer pain Get knowledge on the prescription criteria to give the optimal therapy to the right patient and
on the monitoring of the expected efficacy
Monitoring breakthrough cancer pain Study the differences followed by the expert panel members to monitoring cancer patients
either with or without breakthrough pain
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On the treatment and monitoring of BTcP
In the first questionnaire, participants were asked about the
ideal treatment of BTcP (Fig. 4a). It was mostly reported
that the ideal time to onset of analgesic effect should be
than 15 min (97.8 %), and duration of the analgesic effect
should last maximum of 1–2 h (74.1 %). The panel con-
sidered transmucosal fentanyl (oral or nasal forms) as the
best option to treat BTcP (Fig. 4b).
In the first round, initiation and duration of analgesia,
and the route of administration were the most determinant
criteria to select a drug for BTcP (Table 3). However, ease
of titration, clinical features of each patient and the need of
social support to the patient gained more importance in the
second survey. After selecting a BTcP drug, many experts
(86 %) would carry out a drug titration schedule and
almost all (94 %) draft instructions for self-titration at
home. The number of flares per day, the need to repeat the
dose due to an insufficient relief, and the degree of relief
were the highest-scored items to be registered for the
titration of BTcP medication (Fig. 5).
In the first round, and regarding the timeframe for the
first follow-up visit, each period was evaluated on a Likert
scale of 1–5, where 1 was ‘‘in no case’’ and 5 ‘‘in all cases’’
Fig. 1 Participants (n = 90) responded to the question of the
characteristics to be conveniently considered to define BTcP. Each
topic was classified as ‘essential’, ‘non-essential’ and ‘must not be
considered’. Results obtained from the two rounds of the Delphi study
are expressed as a percentage (%)
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(Fig. 6). After the second round, experts recommended that
the first contact with the patient (including by telephone)
should be performed within the first 48 h following the
initiation/titration period, and follow-up of patients should
be done simultaneously to the scheduled visits and/or
whenever requested by the patient.
Discussion
The Delphi technique chosen for this consensus study has
been successfully used in other research studies of pallia-
tive care [16] to establish tools for evaluating BTcP, as in
the recent Alberta report [17], and it seems to be
appropriate for the purposes of this study. The expert panel
members were selected to achieve a fair distribution across
the four professional profiles involved in the management
of BTcP. All Spanish regions were represented in the
study. However, the level of participation differed among
them, with Catalonia being the least represented.
There is no universally accepted definition of BTcP [18,
19]. Similar to the definitions given by other authors [1–3,
20], the experts consulted agreed to define BTcP as a
transitory exacerbation of pain (lasting less than 60 min),
which occurs spontaneously or in association with a
specific predictable or unpredictable trigger at some time
point during the day in cancer patients, despite relatively
stable and adequately controlled background pain. There is
no agreement on whether the theoretical definition of BTcP
might include that background pain is treated with opioids
or other analgesics, which is in consistency with the con-
troversy found in the literature for different definitions of
BTcP. Only 30 % of the panel judge the use of opioid
analgesics to control the background pain to be essential,
whereas 50 % stated as mandatory the fact of taking
analgesics. The issue of treating breakthrough pain with
rapid-onset opioid drugs must be set apart as a simple
advisable therapy.
Because end-of-dose pain is the result of an inadequate
dose of analgesic or a dosing interval that is too long, the
analgesic regimen used to treat baseline persistent pain
should be reassessed and modified as necessary. This might
explain why end-of-dose pain was not considered BTcP in
this study.Fig. 2 Davies diagnostic algorithm
Table 2 Participants (n = 90) respond to the questions about how often they ask to the patient and the importance of several characteristic
factors of BTcP (see Likert scores)










Pain analgesics taken by the patient* 88.9 10.0 0.6 0.5 6.7
Localization of pain 87.8 10.0 1.2 1.0 6.3
Number of flares per day and/or week 83.3 14.4 1.1 1.2 6.6
Efficacy of drug analgesics* 82.2 12.2 4.4 1.2 6.4**
Intensity of flares (scored with VAS or VNRS) 76.7 16.7 4.4 3.3 6.5
Adherence to the pain therapy 75.6 18.9 3.3 2.2 6.6
Spontaneous or triggered occurrence of pain 75.6 20.0 2.2 2.2 6.5
Irradiation of pain 75.6 15.6 6.7 2.1 6.1
Duration of each flare* 65.6 27.8 5.7 0.9 6.4
Impact of flare on night-sleep 58.9 20.0 16.7 0.4 6.2
Time from start of pain to the highest peak of intensity 57.8 23.3 15.6 3.3 6.0
Similarity (or not) between BTcP and cancer background pain 55.6 32.2 6.7 5.5 5.8
When indicated, data are shown as a percentage and Likert scale ranged from 1 (strongly disagree) to 7 (strongly agree)
VAS visual analogue scale, VNRS visual numerical rating scale
* p value = 0.0430
** Statistical differences among the surveyed medical specialties were observed
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The history of the patient with an exacerbation of cancer
pain should include a diagnostic method of BTcP. Litera-
ture recommends the use of Davies algorithm (Fig. 2) [8],
modified from the original published by Davies in 2009 [3].
Although 66 % of respondents recognise not to use it
properly as an algorithm, almost all panellists ask, and
recommend asking, about the three issues enclosed in the
algorithm: the occurrence of background pain, its adequate
control, and pain exacerbations.
To enable proper monitoring of BTcP, participants in
the study recommend the use of a ‘Patient Diary’. Infor-
mation to be mainly recorded in such a diary was the date
Fig. 3 Participants (n = 90)
respond to the questions about
what information (items on the
left edge) should be written
down on the clinical history of
the patient and the importance
of each of these items (see the
Likert score column). When
indicated, data are shown as a
percentage. Likert score ranged
from 1 (strongly disagree) to 7
(strongly agree). *Statistical
differences among the surveyed
medical specialties were
observed
Fig. 4 Participants (n = 90) respond to the characteristics of the
ideal treatment to manage BTcP (a) and the most recommended
breakthrough analgesic drug (b). When indicated, data are shown as a
percentage (a). The best medication (b) was scored using a Likert
scale ranged from 1 (strongly disagree) to 7 (strongly agree).
*Statistical difference among medical specialties (p = 0.0086)
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and time of each episode, its duration and intensity, the
administered rescue dose, time to relief and degree of
relief, side effects, and information about the drug titration
phase.
Many authors suggest that BTcP should be assessed
before the start of a certain therapy and afterwards, at
regular intervals until an adequate pain control is achieved
[2]. Most panellists recommended that patients should
contact their doctor 48 h after initiated the therapy, and
later if they need more than three rescue doses per day.
In our study, the greatest importance is given to the
knowledge of the opioid analgesics taken by the patient for
pain, separately from those that are prescribed to control
BTcP. The number of flares per day or week, their duration
and intensity, the degree of adherence to treatment and its
efficacy, and the type of breakthrough pain (spontaneous or
incidental) were other factors stated by the experts. This
was aligned to that reported by literature. Previous studies
report that a proper assessment of breakthrough pain should
include frequency and duration of episodes, intensity and
type of pain, precipitating factors, previous medication and
effectiveness of rescue therapy [21].
Surprisingly, there is no unanimity about the impact of
BTcP on the quality of life of patients. Some studies show
the great impact that BTcP has on mood and functional
status [22]. BTcP is described as a frequent complication,
Fig. 5 Participants (n = 90)
were asked to score the
importance of several items to
be registered for the titration of
BTcP medication. Items were
scored using a Likert scale





Table 3 Participants (n = 90) were asked to score the importance of several items to be considered for the prescription of the future BTcP
medication
Item Likert score (round 1) Likert score (round 2) p value
(round 2 vs round 1)
Initiation of analgesia action 6.5
Route of administration 6.3
Duration of analgesia action 6.2
Ease of titration 6.1 6.4 (p = 0.0020)
Clinical features of patients 5.9 6.2 (p = 0.0157)
Social support of the patient 5.5 5.9 (p = 0.0376)
Pharmacokinetic properties 5.3
Patient is treated with opioid analgesics to control background pain* 4.9
Drug availability at the hospital 3.9
Bars show the results obtained from the first round of the Delphi study. When indicated, those items with significant differences between Round 2
and Round 1 are also shown. Items were scored using a Likert scale ranged from 1 (unimportant) to 7 (extremely important)
* Patients taking at least 60 mg/day oral morphine, 25 lg/h transdermal fentanyl, 30 mg/day oxycodone, 8 mg/day oral hydromorphone or an
equivalent dose of other opioid analgesics for a week or longer
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of sudden onset, short duration and moderate to severe
intensity, and with a very negative impact on quality of life
at physical (disability, insomnia), psychological (anxiety,
depression) and social levels (unemployment, social iso-
lation) [23]. This contradiction might be explained by the
lack of time of physicians, or by the absence of specific
protocols to record all these data.
Breakthrough pain is not a single condition, but an
assortment of very different conditions. Professionals
identified the importance to develop protocols for the
management of cancer pain, including BTcP. Primary care
and nursing should be also involved in the preparation of
such protocols.
Regarding the characteristics of the treatment, partici-
pants believe that the ideal therapy of BTcP must meet
these conditions: a short-acting effect (the time to onset of
analgesic effect is less than 15 min), the analgesia lasts as
longest as 1–2 h, and the route of administration is trans-
mucosal (oral or nasal). In the present study, immediate-
release fentanyl is chosen by the majority of specialists as
the drug of choice to treat BTcP. This is due to its phar-
macokinetic properties as well as its rapid onset of action.
The selection of one or another presentation and route of
administration (oral or nasal) will depend primarily on the
clinical situation and the personal preferences of the
patient. In the literature, the treatment of BTcP involves
strategies such as the treatment of cancer disease, modifi-
cation of the baseline analgesic treatment, non-pharmaco-
logical interventions, and an appropriate rescue medication
[24]. The ideal opioid for this treatment should have a rapid
onset of action (short time interval between administration
and the presence of minimum effective concentrations in
the bloodstream), be sufficiently powerful, and have a short
duration of action [25].
According to the presentation ‘‘New approaches to the
diagnosis and treatment of breakthrough cancer pain con-
sensus document’’ at the XIV Simposio de Revisiones en
Ca´ncer (Madrid), the rescue dose is not related to the
baseline opioid dosage. Our panel believes it is essential to
carry out titration of the rescue medication, which can be
done at patient’s home by means of a previously drafted set
of instructions, and recording the recommended informa-
tion in the ‘Patient Diary’ in a particular manner during this
phase: number of flares per day, any need to repeat the dose
because of insufficient pain relief, and the degree of relief
obtained. In this way the efficacy and tolerability of the
treatment can be evaluated and any changes in the nature of
BTcP can be recognised [6]. We recommend a first
assessment contact within the first 48 h of the drug titration
schedule. Further monitoring of BTcP can be managed
using routine scheduled visits to the patient and/or subject
to patient’s request.
Conclusions
Regarding the characteristics that best define BTcP, there
was a broad agreement that the baseline pain should be
controlled, but not necessarily with opioids; there must be
exacerbations; the duration of the episode should be less than
an hour, and the intensity of pain greater than 7 out of 10.
There was no agreement about whether the number of
daily episodes of BTcP has to be less than four to consider
that the baseline pain is controlled. The need to treat
Fig. 6 Participants (n = 90)
responded about the time-frame
for the first follow-up visit after
initiating the treatment of BTcP.
Possible responses were scored
using a Likert scale ranged from
1 to 5 (1, in no case– 5, in all
cases)
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background pain with opioids was also a matter for
controversy.
There is consensus in considering that BTcP is not the
same as end-of-dose effect.
Questions encompassed in the Davies algorithm should
be asked to diagnose BTcP.
The best tool for assessing and monitoring BTcP is the
‘Patient Diary’, either as a standardized document, or in the
form of some generic recommendations on patient outcome
records for the referral to the doctor. This should record the
date and time of each episode, duration and intensity of
each flare, administered rescue dose, time to pain relief,
degree of relief and side effects. ‘Patient Diary’ should also
include instructions for titration, the recommendation to
contact the doctor within the first 48 h of initiating the
therapy and/or if more than three rescues per day are
required, and a contact phone number. The diagnose of
BTcP should be logged in the patient’s clinical record.
Protocols for the diagnosis, assessment and monitoring of
BTcP are needed and these should take into account the
roles of all the professionals involved, including primary
care and nursing teams.
The optimal drug to treat BTcP should have a rapid
onset of action (15 min or less), short-acting effect (B2 h)
and an easy route of administration (transmucosally).
Fentanyl, either in its oral or nasal transmucosal form is
well established as the best active substrate that fits better
this profile.
Drug titration can be done at patient’s home. Instruc-
tions are advised to be provided, so that the patient gathers
the information from the titration phase to be included on
the patient diary: number of flares per day, need to repeat
the dose because of an insufficient relief from the flare, and
degree of relief.
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